Analyst consensus rating
Enliven Therapeutics Analyst Rating: Strong Buy
Direct answer
Enliven Therapeutics's consensus rating is Strong Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $74.33.
Forecast evidence checked November 21, 2026.
Get free Enliven Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $46.53
- Average price target
- $74.33
- High price target
- $82.00
- Low price target
- $69.00
- Low target gap
- +48.3%
- Target upside
- +59.8%
- High target gap
- +76.2%
- Target range width
- 27.9%
- Consensus rating
- Strong Buy
- Analysts
- 12
- Evidence date
- November 21, 2026
- Valid through
- November 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Enliven Therapeutics?
Enliven Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $74.33.
How far are Enliven Therapeutics's low and high targets from the recorded price?
The low target implies +48.3%, while the high target implies +76.2%.
How many analysts are included in Enliven Therapeutics's consensus?
The verified consensus includes 12 analysts.
How is Enliven Therapeutics's target upside or downside calculated?
The average target of $74.33 is divided by the recorded price of $46.53, then one is subtracted to produce +59.8%. This does not guarantee a future return.
When was Enliven Therapeutics's analyst forecast verified?
The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.